GHRH / GHS Blend Comparator

The GHRH / GHS Blend Comparator is a two-vial set containing CJC-1295/Ipamorelin at 5 mg/5 mg and Tesamorelin/Ipamorelin at 6 mg/3 mg. Both pair a GHRH-receptor agonist with the GHS-R1a ligand Ipamorelin. The blends differ in two respects — the GHRH component and the ratio — so the set compares formulations rather than isolating a single variable.

Key Takeaways

• The GHRH / GHS Blend Comparator contains one CJC-1295/Ipamorelin 5/5 vial and one Tesamorelin/Ipamorelin 6/3 vial, both premixed and lyophilized.
• The notation gives mass per component: a 5/5 vial contains 10 mg in total, a 6/3 vial contains 9 mg.
• The two blends differ in both the GHRH component and the ratio, so a difference between them cannot be attributed to either factor alone.
• Combining GHRH-receptor agonists with GHS-R1a ligands has a documented basis at class level in published work.
• No published trial has established that either specific ratio is optimal or that either formulation has been validated.
• Both blends are supplied strictly for laboratory research and are not intended for human consumption, therapeutic use, veterinary use, or diagnostic applications.

What’s Included in This Comparator Set

Both are supplied as premixed lyophilized powder in a single vial each, with batch documentation.

What the 5/5 and 6/3 notation means

Each number gives the mass of one component in milligrams, not the vial total. A 5/5 vial contains 5 mg of CJC-1295 and 5 mg of Ipamorelin — 10 mg in total. A 6/3 vial contains 6 mg of tesamorelin and 3 mg of Ipamorelin — 9 mg in total.

This convention is used consistently across premixed blends in this catalogue, including the BPC-157 / TB-500 blend formats.

Two Formulations, Two Differences

Both blends share an architecture: one GHRH-receptor agonist plus Ipamorelin. Two things separate them.

The GHRH arm differs

One blend uses CJC-1295, the other tesamorelin. These are different compounds — different sequence basis, different stabilisation approach, different molecular size. They are not interchangeable, and swapping one for the other is the more substantial of the two differences between these products.

The ratio differs

The CJC-1295 formulation is 1:1. The tesamorelin formulation is 2:1, with the GHS component at half the mass of the GHRH component.

Because both factors change together, this is a formulation comparison rather than a controlled one. A difference observed between the two blends cannot be attributed to the GHRH component or to the ratio, because neither was held constant.

That is worth stating plainly. Researchers wanting to isolate one variable need components supplied separately, not premixed — see the GHRH Analog Comparator and the GHS-R Ligand Comparator.